Metastatic Breast Cancer Market

Report Overview

According to the deep-dive market assessment study conducted by Growth Plus Reports, the global metastatic breast cancer market was valued at US$ 17 billion in 2021 and is expected to register a revenue CAGR of 9.8% to reach US$ 39.43 billion by 2030.

Market Fundamentals

Breast cancer is one of the most common forms of cancer and has been a major health concern for many years. With the advancements in technology, there have been significant changes in the way breast cancer is treated and diagnosed. According to medical terminology, advanced/metastatic breast cancer is a type of cancer that has spread from the breast to other vital organs, like the bones, lungs, liver, or brain, to name a few. When a person has stopped receiving treatment for an early stage or cancer has a locally advanced form of the breast, such as stage I, II, or III, metastatic breast cancer typically appears months or years later. Because of this, metastatic breast cancer is also referred to as distance recurrence breast cancer.

According to the American Cancer Society, the number of women in the U.S. diagnosed with metastatic breast cancer has increased from 12,000 in 1975 to 40,000 in 2017. This increase is due to the advancement of screening technologies that allow earlier cancer detection and diagnosis. Additionally, most women live longer with breast cancer, increasing metastasis cancer chances. Treatment for metastatic breast cancer can vary depending on the type and stage of cancer. However, common treatments include chemotherapy, radiation therapy, and surgery. Clinical trials are available to explore new treatment options in some cases. Chemotherapy and radiation therapy are the most frequently recommended treatments for metastatic breast cancer. Both therapies aid in reducing tumor growth. Contrarily, hormone therapy is the most effective treatment since it helps slow the proliferation of cancer cells.

[497850]

Market Dynamics

During the forecast period, the global metastatic breast cancer market revenue growth is expected to be driven by an increase in global awareness and the development of novel therapies and medications. Due to the fast-paced business culture and the rise of working from home after COVID-19, workplace stress has escalated. Additionally, sedentary habits have contributed to several health issues. These factors have raised breast cancer incidence, increasing the demand for breast cancer treatments. Lack of exercise, a stressful daily schedule, and denial of health problems contribute to the rise in breast cancer cases. 

The growing rates of metastatic breast cancer have paved the way for new treatments like tumor-agnostic therapy, HER2-targeted therapy, ovarian suppression, whole-brain radiation therapy, immunotherapy, stereotactic radiosurgery, and fractionated stereotactic radiation therapy, all of which are assisting in the market revenue expansion. To provide new drugs and treatment methods (such as blood tests for tumor markers) for the disease, numerous breast cancer therapeutics market incumbents make significant investments in drug discovery and development activities. In the subsequent years, it is anticipated that higher investments in R&D and rising cancer diagnostics awareness campaigns are expected to raise market revenue significantly. The lack of efficient medicines and side effects from those treatments may constrain the expansion of the global metastatic breast cancer market revenue. The high cost of treating metastatic breast cancer can limit market revenue growth to some extent.

Market Ecosystem

The global metastatic breast cancer market has been analyzed from three perspectives, such as treatment type, end user, and region.

Metastatic Breast Cancer Market by Treatment Type

[974880]

Based on treatment type, the global metastatic breast cancer market has been segmented into chemotherapy, biologically targeted therapy, radiation therapy, hormone therapy, and breast surgery. 

The targeted therapy segment accounts for the largest revenue share in the global metastatic breast cancer market. This commanding revenue share results from fresh developments, the ability to mix with other medications, and the emergence of a tailored approach to improve clinical outcomes. A variety of molecules in targetable pathways, such as the epidermal growth factor receptor (EGFR), poly (adenosine diphosphate-ribose) polymerase (PARP), and cyclin-dependent kinase 4/6 (CDK4/6) are now included in the scope of targeted medicines because of ongoing clinical trials. 

Hormone therapy is expected to rise exponentially during the forecast period. These are the most common treatment for premenopausal women, slowing the multiplication of cancer cells.

Metastatic Breast Cancer Market by End User

Based on end users, the global metastatic breast cancer market is segmented into hospitals, clinics, and others. 

Hospitals and clinics segment accounts for the largest share in the global metastatic breast cancer market due to the rising number of hospitals and clinics in developing countries, the availability of a wide range of technologies for treatment and procedures (uses of monoclonal antibodies), and the availability of different metastatic breast cancer treatment drugs (small molecule inhibitors). Due to the major investments from the public and commercial sectors, there are more cancer research facilities and labs available. 

Metastatic Breast Cancer Market by Region 

Based on region, the global metastatic breast cancer market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global metastatic breast cancer market in terms of the largest revenue share. North American nations such as the United States are promoting breast cancer patient awareness campaigns, which are expected to support the expansion of the overall North American breast cancer market revenue. The need for metastatic breast cancer therapy in North America is expected to increase with the rising prevalence of cancer. Additionally, strategic developments, such as introducing new therapies, player acquisitions, and mergers, is fuelling market revenue expansion. 

Asia Pacific is expected to grow at the fastest revenue CAGR during the forecast period because of the rising breast cancer prevalence and a number of geriatric population in this region. 

Europe is expected to represent a significant revenue share in the global metastatic breast cancer market due to its successful technological advancements and the high prevalence of diseases in this region.

Competitive Landscape

The prominent players operating in the global metastatic breast cancer market are: 

• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson Services Inc.
• Novartis AG
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Abbvie Inc.
• Pfizer Inc.
• Bristol Myers Squibb Company
• Gilead Sciences Inc.
• Sun Pharmaceutical Co. Ltd. 
• Bayer AG
• AstraZeneca PLC

Strategic Developments

• In June 2022, the U.S. FDA gave Novartis' Dabrafenib and Trametinib combination the go-ahead to treat solid metastatic tumors that are unresectable and carry the BRAF mutation in all age groups. The human gene BRAF produces the B-Raf protein. The gene is also known as v-Raf murine sarcoma viral oncogene homolog B and proto-oncogene B-Raf.
• In May 2022, Opdivo (nivolumab) from Bristol Myers Squibb and Yervoy (ipilimumab) received approval from the European Commission (EC) for use as the first-line therapy for adult patients with unresectable advanced, recurring, or metastatic esophageal squamous cell carcinoma (ESCC). Results from the Phase 3 clinical studies, reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2021, served as the foundation for the EC's decision.

Frequently Asked Questions About This Report